OncoMatch/Clinical Trials/NCT06762782
Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
Is NCT06762782 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Postoperative adjuvant lenvatinib for hepatocellular carcinoma (hcc).
Treatment: Postoperative adjuvant lenvatinib — This study is a prospective, randomized, controlled, open, phase II, multicenter clinical study, which aims to evaluate the efficacy and safety of lenvatinib for adjuvant treatment of high-risk recurrent liver cancer after radical surgery. This study is divided into 3 stages: screening period (screening period 28 days), treatment period (up to 12 months, or until any of the following occurs, whichever occurs first: ① The subject has an intolerable toxic reaction and is still not relieved after dose adjustment; ② The subject's first imaging confirmed disease recurrence or withdrew from the study for other reasons), and follow-up period (12 months after the end of treatment). Dosage regimen: Eligible subjects were randomly assigned to the experimental group or the control group in a 2:1 ratio, with surgical method (radical surgery vs ablation) as the stratification factor. The experimental group received lenvatinib treatment, and the control group received best supportive care
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Disease stage
Grade: edmondson iiiedmondson iv (edmondson)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: curative surgery or ablation — adjuvant
Received radical treatment surgery for liver cancer within 4 to 8 weeks prior to enrollment
Cannot have received: targeted drug therapy (sorafenib, lenvatinib, regorafenib)
Received targeted drug therapy such as sorafenib, lenvatinib, regorafenib, or immunomodulatory therapy such as anti-PD-1, anti-PD-L1, anti-CTLA-4 before surgery
Cannot have received: immunomodulatory therapy (anti-PD-1, anti-PD-L1, anti-CTLA-4)
Received targeted drug therapy such as sorafenib, lenvatinib, regorafenib, or immunomodulatory therapy such as anti-PD-1, anti-PD-L1, anti-CTLA-4 before surgery
Cannot have received: antitumor treatment
no antitumor treatment before surgery
Cannot have received: reoperation for recurrent liver cancer
Reoperation for recurrent liver cancer
Lab requirements
Blood counts
hemoglobin ≥90 g/l; anc ≥1.5×10^9/l; platelet count ≥75×10^9/l
Kidney function
creatinine ≤1.5×uln
Liver function
albumin ≥28 g/l; total bilirubin ≤1.5×uln; ast, alt ≤3×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06762782 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages